

University of Groningen

## **Carnosine Prevents Apoptosis of Glomerular Cells and Podocyte Loss in STZ Diabetic Rats**

Riedl, Eva; Pfister, Frederick; Braunagel, Margarita; Brinkkoetter, Paul; Sternik, Paula; Deinzer, Martina; Bakker, Stephan J. L.; Henning, Rob H.; van den Born, Jacob; Kraemer, Bernhard K.

*Published in:*  
Cellular physiology and biochemistry

*DOI:*  
[10.1159/000331740](https://doi.org/10.1159/000331740)

**IMPORTANT NOTE:** You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

*Document Version*  
Publisher's PDF, also known as Version of record

*Publication date:*  
2011

[Link to publication in University of Groningen/UMCG research database](#)

*Citation for published version (APA):*

Riedl, E., Pfister, F., Braunagel, M., Brinkkoetter, P., Sternik, P., Deinzer, M., Bakker, S. J. L., Henning, R. H., van den Born, J., Kraemer, B. K., Navis, G., Hammes, H-P., Yard, B., & Koepfel, H. (2011). Carnosine Prevents Apoptosis of Glomerular Cells and Podocyte Loss in STZ Diabetic Rats. *Cellular physiology and biochemistry*, 28(2), 279-288. <https://doi.org/10.1159/000331740>

### **Copyright**

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

### **Take-down policy**

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

*Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.*

## Carnosine Prevents Apoptosis of Glomerular Cells and Podocyte Loss in STZ Diabetic Rats

Eva Riedl<sup>1,\*</sup>, Frederick Pfister<sup>1,\*</sup>, Margarita Braunagel<sup>1</sup>, Paul Brinkkötter<sup>1,2</sup>, Paula Sternik<sup>1</sup>, Martina Deinzer<sup>3</sup>, Stephan J.L. Bakker<sup>4</sup>, Rob H. Henning<sup>5</sup>, Jacob van den Born<sup>4</sup>, Bernhard K. Krämer<sup>1</sup>, Gerjan Navis<sup>4</sup>, Hans-Peter Hammes<sup>1</sup>, Benito Yard<sup>1</sup> and Hannes Koeppel<sup>1</sup>

<sup>1</sup>5<sup>th</sup> Medical Clinic, University Medicine Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, <sup>2</sup>Renal Division, Department of Medicine, University of Cologne, Cologne, <sup>3</sup>Institute of Clinical Chemistry, University Medicine Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, <sup>4</sup>Department of Internal Medicine, Division of Nephrology, University Medical Center Groningen, Groningen, <sup>5</sup>Department of Clinical Pharmacology, University Medical Center Groningen, Groningen,

\*Eva Riedl and Frederick Pfister contribute equally

### Key Words

Diabetic nephropathy • Carnosine • Apoptosis • Podocytes

### Abstract

**Background/Aims:** We identified carnosinase-1 (CN-1) as risk-factor for diabetic nephropathy (DN). Carnosine, the substrate for CN-1, supposedly is a protective factor regarding diabetic complications. In this study, we hypothesized that carnosine administration to diabetic rats might protect the kidneys from glomerular apoptosis and podocyte loss. **Methods:** We examined the effect of oral L-carnosine administration (1g/kg BW per day) on apoptosis, podocyte loss, oxidative stress, AGEs and hexosamine pathway in kidneys of streptozotocin-induced diabetic Wistar rats after 3 months of diabetes and treatment. **Results:** Hyperglycemia significantly reduced endogenous kidney carnosine levels. In parallel, podocyte numbers significantly decreased (-21% compared to non-diabetics,  $p < 0.05$ ), apoptotic glomerular cells numbers increased (32%, compared to non-diabetic,  $p < 0.05$ ) and protein levels of bax and cytochrome c

increased (175% and 117%). Carnosine treatment restored carnosine kidney levels, prevented podocytes loss (+23% compared to diabetic,  $p < 0.05$ ), restrained glomerular apoptosis (-34% compared to diabetic;  $p < 0.05$ ) and reduced expression of bax and cytochrome c (-63% and -54% compared to diabetics, both  $p < 0.05$ ). In kidneys of all diabetic animals, levels of ROS, AGEs and GlcNAc-modified proteins were increased. **Conclusion:** By inhibition of pro-apoptotic signaling and independent of biochemical abnormalities, carnosine protects diabetic rat kidneys from apoptosis and podocyte loss.

Copyright © 2011 S. Karger AG, Basel

### Introduction

Diabetic kidney disease (DKD) is a frequent complication of both diabetes mellitus type 1, and type 2. About one third of patients with DKD will progress to overt diabetic nephropathy (DN) within 5-15 years. ROS pro-

duction, non-enzymatic glycosylation and an increased flux through the hexosamine pathway are important biochemical changes in hyperglycaemic patients and that are causally linked to the development of DN [1-3]. Early in the development of DN, these biochemical changes cause apoptosis of different glomerular cells [4-6], thereby promoting the development of DN [7, 8]. Apoptosis of glomerular cells is supposed to be causally related to DN, as development of DN can completely be prevented by inhibiting apoptosis in the glomerulus [9].

At the onset of DN, podocytes are key targets for glomerular injury [10-13]. Podocytes loss occurs either by apoptosis or by detachment from the glomerular basement membrane [5]. Hence, numbers of podocytes per glomerulus gradually decline in the course of DN [11] and this change is highly predictive of both progressive glomerular injury and long-term albumin excretion in diabetic patients [14]. Thus, podocyte apoptosis seems to precede the development of DN and determines at least in part kidney function in diabetic patients.

In contrast to other diabetic complications, only 20-40% of diabetic patients are susceptible to develop DN which seems to be genetically determined [15, 16]. We recently identified a polymorphism in the signal sequence of the *CNDPI* gene, encoding the serum carnosinase (CN-1), to be associated with susceptibility to DN. Since DN occurs significantly less frequent in diabetic patients that are homozygous for the shortest allelic form, i.e. (CTG)<sub>5</sub> (the so-called *CNDPI Mannheim allele*), the Mannheim-allele appears to be protective in terms of susceptibility to DN [17]. This can be explained by the fact that the (CTG)<sub>5</sub> allele corresponds with a low CN-1 secretion efficiency [18] and hence with a low serum CN-1 enzyme activity [17, 19]. Because carnosine, the natural substrate for CN-1, has potential intrinsic renal protective properties [20-24] a low CN-1 expression or activity is beneficial for diabetic patients. Carnosine may prevent apoptosis [25-27] and up-regulates defensive mechanisms such as heat shock proteins [28].

Short-term carnosine administration has been shown to protect against ischemia-reperfusion damage [29-33], and chronic oral carnosine administration can retard onset of diabetes in db/db mice [34]. However, whether carnosine can protect against DN has not been investigated yet. In the present study we therefore tested the effect of oral carnosine administration on early diabetic changes in STZ-induced diabetic rat kidneys, i.e. biochemical abnormalities, glomerular cell apoptosis and podocyte loss.

## Materials and Methods

### *Animals and Diabetes Induction*

The study was performed in accordance with the ARVO statement for the use of animals in ophthalmic and vision research and all animal procedures were approved by the Regierungspräsidium Karlsruhe. Male Wistar rats (Harlan Laboratories, Inc.) were housed in a 12h light/dark cycle with free access to food and drinking water. Animals were randomly divided into three groups: 24 non-diabetic rats, 46 diabetic rats and 32 diabetic rats substituted with carnosine. Rats of the diabetic groups were rendered diabetic by intravenous injection of streptozotocin (45mg/kg, Roche, Mannheim, Germany) diluted in citrate buffer (pH 4.5). Animals were considered diabetic when blood glucose reached stable levels over 250 mg/dl. Insulin was occasionally given to individual diabetic rats to prevent critical weight loss. Metabolic data (body weight and blood glucose) were measured every week and blood samples for the determination of glycated haemoglobin concentration by affinity chromatography (MicromatII™; Bio-Rad Laboratories GmbH, Munich, Germany) were collected at the end of the study (n= 7-9 per group). All rats were sacrificed after 3 month of diabetes. Kidneys were taken out immediately and washed carefully in ice cold PBS. For histology and immunohistochemistry, kidneys were subsequently fixed in 4% formalin. For western blot analysis, kidney cortex was isolated, washed thoroughly and frozen at -80°C until further processing.

### *Carnosine Supplementation*

Diabetic Wistar rats were divided into two groups one week after diabetes induction. One diabetic control group, receiving pure water and a second diabetic group receiving water supplemented with 1 g of carnosine/kg body weight (Flamma S.p.a., Chignolo d'Isola, Italy). Carnosine was dissolved in the daily drinking volume. Water consumption and body weights of each cage were assessed once a week. L-carnosine-supplemented drinking water and lightproof bottles were replaced every day. Carnosine concentration in kidney tissue was measured fluorometrically by high-performance liquid chromatography as previously described by Janssen et al. [17] and Schonherr [35].

### *Renal histology*

2 micrometer kidney paraffin sections were stained with periodic acid-Schiff (PAS) and hematoxylin according to standard staining protocols. An investigator evaluated kidney histopathology in a blinded fashion and graded the glomerular damage including mesangial matrix expansion, hyalinosis with focal adhesion, capillary dilation, glomerular tuft occlusion and sclerosis.

### *Detection of glomerular cell apoptosis*

DNA strand breaks in apoptotic cells were visualized in 4 micrometer kidney paraffin sections using terminal transferase dUTP nick-end labelling (TUNEL, In Situ Cell Death Detection Kit, POD; Roche, Mannheim, Germany) according to the manufacturer's instructions. In brief, sections were deparaffinised and treated with 2% H<sub>2</sub>O<sub>2</sub> /Methanol to block endogenous

peroxidase. Thereafter, slides were incubated with the TUNEL reaction mixture containing TdT and fluorescein d-UTP. After incubation, incorporated fluorescein was detected with an anti-fluorescein antibody conjugated with POD. Finally, the immunocomplexed POD was visualized by a substrate reaction using the DAB Peroxidase substrate kit (Vector Laboratories/ LINARIS Biologische Produkte GmbH, Wertheim, Germany), followed by nuclear counterstaining. TUNEL positive nuclei were counted in 10 randomly selected kidney glomeruli per animal by two independent persons and their numbers were expressed relative to the corresponding glomerular area as assessed by an image analyzing system (CUE-2; Olympus Optical, Hamburg, Germany).

#### *Quantification of podocyte loss*

Paraffin-embedded, formalin-fixed, 3- $\mu$ m-thick kidney sections were deparaffinised, treated with 2%  $H_2O_2$  /methanol to block endogenous peroxidase, and microwaved at 500 W and 270 W for 10 min each in citrate buffer. The sections were then incubated with a polyclonal antibody to Wilms' tumor 1 protein (Santa Cruz biotechnology Inc., Heidelberg, Germany) for 1 h at room temperature. After incubation with an appropriate POD coupled secondary antibody, POD was visualized by a substrate reaction using the DAB Peroxidase substrate kit (Vector Laboratories/ LINARIS Biologische Produkte GmbH, Wertheim, Germany), followed by nuclear counterstaining.

Podocytes were identified according to cell shape, localization and positivity to wt-1 staining. Total numbers of podocytes were counted in kidney sections of randomly selected animals by two independent persons in 10 randomly selected kidney glomeruli per animal. The data are expressed as podocyte numbers relative to the corresponding glomerular area as assessed by an image analyzing system (CUE-2; Olympus Optical, Hamburg, Germany).

#### *Western Blot*

In order to isolate proteins from kidney cortex, frozen tissue was homogenized mechanically on ice. Proteins were extracted from lysates using a lysis buffer containing 125 mM NaCl, 10 mM EDTA, 25 mM Hepes, 10 mM  $Na_3VO_4$ , 0.5 % deoxycholic acid, 0.1 % SDS, 1% Triton-X-100, phosphatase-Inhibitor (Sigma, Steinheim, Germany) and Protease-Inhibitor (Roche, Mannheim, Germany). Insoluble debris was removed by centrifugation at 14,000g at 4°C for 10 minutes. Protein extracts were heated in Laemmli-sample buffer (Bio-Rad Laboratories GmbH, Munich, Germany) for 5 min at 100°C prior to separation by SDS-PAGE. Thereafter, proteins were electrophoretically transferred to a PDVF membrane. Depending on the primary antibody applied, membranes were blocked with either 5 % skimmed milk or 5 % BSA in TBS according to the manufacturer's recommendations. For detection of apoptosis signalling, antibodies against cytochrome c and Bax (Cell Signalling Technology, Danvers, USA) were utilized. Biochemical changes in the kidney were detected by antibodies directed against carboxymethyl-lysine- (CML, [36]), nitrotyrosine- (Alexis Biochemicals, Axxora Deutschland GmbH, Germany), methylglyoxal (methylglyoxal-H1, [37]) and N-Acetylglucosamine-modified proteins (Abcam plc, Cam-

bridge, United Kingdom). All antibodies were diluted and incubated as recommended by the manufacture. Immunoblots were made visible on Amersham Hyperfilms (Amersham, Buckinghamshire UK) by incubating the membranes with appropriate HRP-coupled secondary antibodies (Santa Cruz Biotechnology, Heidelberg, Germany) and by using enhanced chemiluminescence (PerkinElmer, LAS, USA). For loading control, membranes were stripped and re-probed with antibodies directed against GAPDH (GAPDH antibody - Loading Control, Abcam plc, Cambridge, United Kingdom). Intensity of the bands was measured by densitometry using the ImageJ 1.36b software.

#### *Statistical analysis*

All data are expressed as mean  $\pm$  SD. Data analysis was performed by using unpaired two-tailed student T-test and a P value less than 0.05 was considered as statistically significant.

## **Results**

All diabetic rats developed stable hyperglycemia of more than >250 mg/dl two weeks after diabetes induction. Average blood glucose levels were significantly elevated in the diabetic rats (Fig. 1B; measurement at 3 month: non-diabetic vs. diabetic:  $123 \pm 36$  mg/dl and  $585 \pm 26$  mg/dl;  $p < 0.05$  and non-diabetic vs. diabetic with carnosine:  $123 \pm 36$  mg/dl and  $592 \pm 14$  mg/dl;  $p < 0.05$ ; diabetic vs. diabetic with carnosine not significant). The increase in body weight was significantly impaired after the onset of hyperglycemia resulting in reduced body weights at the end of the study (non-diabetic vs. diabetic:  $457 \pm 35$  g and  $282 \pm 25$  g;  $p < 0.05$  and non-diabetic vs. diabetic with carnosine:  $457 \pm 35$  g and  $292 \pm 38$  g;  $p < 0.05$ ; diabetic vs. diabetic with carnosine not significant; Fig. 1A). Glycated haemoglobin levels were 2.3 fold increased in diabetic rats and 1.9 fold in diabetic rats supplemented with carnosine (non-diabetic vs. diabetic:  $5.9 \pm 0.4$  % and  $13.4 \pm 3.4$  %;  $p < 0.05$  and non-diabetic vs. diabetic with carnosine:  $5.9 \pm 0.4$  % and  $11.2 \pm 2.8$ ;  $p < 0.05$ ; diabetic vs. diabetic with carnosine not significant; Fig. 1C). As depicted in Fig. 1D, carnosine levels were significantly decreased in diabetic kidneys (-98% compared to non-diabetic; non-diabetic vs. diabetic:  $150.0 \mu\text{g/g} \pm 3.5$  and  $3.3 \mu\text{g/g} \pm 0.7$ ;  $p < 0.05$ ) two weeks after diabetes induction. In diabetic rats that were fed with carnosine, renal carnosine concentrations increased significantly (diabetic vs. diabetic with carnosine:  $3.3 \mu\text{g/g} \pm 0.7$  and  $300.0 \mu\text{g/g} \pm 102.8$ ;  $p < 0.05$ ) and were higher than in non-diabetic rats (+89% compared to non-diabetic; non-diabetic vs. diabetic with carnosine, p not significant). Kidney histopathology was examined in PAS and hematoxylin stained kidney sections. Mild glomerulosclerotic changes,


**Fig. 1.** The influence of oral carnosine treatment on STZ-induced hyperglycaemia and renal carnosine levels. Body weights (*Panel A*) and blood glucose levels (*Panel B*) of non-diabetic (NC, ●), diabetic (DC, □) and diabetic rats treated with carnosine (DC+C, ▲) were monitored over 12 weeks. In comparison to non-diabetic controls, all diabetic animals developed stable hyperglycemia and showed reduced body weights. Moreover, after 3 months levels of HbA1c were elevated in the diabetic animals. This was independent of carnosine treatment  $*=p<0.05$  vs NC (*Panel C*). Measurement of renal carnosine by HPLC (*Panel D*) revealed that endogenous carnosine levels are reduced in diabetic animals and oral carnosine treatment increased renal carnosine levels above that of non diabetic controls  $*=p<0.05$  vs NC,  $\#p<0.05$  vs NC.

indicating an early and not advanced stage of a diabetic kidney damage, were found in the diabetic animals. No significant difference was found between the treated and the non treated group (Fig. 2).

To evaluate the effect of carnosine treatment on glomerular apoptosis, DNA strand breaks were assessed by in situ TUNEL staining. Three months after the onset of diabetes the numbers of TUNEL positive cells were significantly increased in non-treated diabetic rats (+32% compared to non-diabetics, non-diabetics:  $0.0014 \pm 0.0007$  TUNEL+ cells/glomerular area and diabetics:  $0.0019 \pm 0.00018$  TUNEL+ cells/glomerular area,  $p<0.05$ , Fig. 3A, B). In carnosine treated diabetic animals, the numbers of TUNEL positive cells were reduced by -40% compared to diabetic animals (diabetics:  $0.0019 \pm 0.00018$  TUNEL+ cells/glomerular area and diabetics with carnosine:  $0.0013 \pm 0.00007$  TUNEL+ cells/glomerular area,  $p<0.05$  compared to diabetics, diabetics with carnosine vs. non-diabetics not significant, Fig. 3A, B).


We further investigated the anti-apoptotic potential of carnosine by western blot analysis of kidney cortex lysates. Immunoblots stained for pro-apoptotic bax and cytochrome c displayed an increased expression of +175%, and +117% respectively in the diabetic kidneys of non-treated rats ( $p<0.05$  for both, Fig. 3C-F). Carnosine treatment significantly inhibited hyperglycemia-induced upregulation of bax (-63% compared to diabetics,  $p<0.05$ ) and cytochrome c (-54% compared to diabetics,  $p<0.05$ ) in diabetic kidneys (Fig. 3C-F).

To investigate whether carnosine treatment can prevent podocyte loss in diabetic rats, we determined glomerular podocyte numbers using wt-1 as podocyte marker in histological kidney sections. Podocytes numbers were significantly reduced in diabetic kidneys (-21% compared to non-diabetics, non-diabetics:  $0.0018 \pm$




$0.00023$  WT-1+ cells/glomerular area and diabetics:  $0.0014 \pm 0.00018$  WT-1+ cells/glomerular area,  $p<0.05$ , Fig. 4A, B), while in diabetic rats fed with carnosine, podocyte numbers were normalized (+23% compared to diabetics, diabetics:  $0.0014 \pm 0.00018$  WT-1+ cells/

**Fig. 2.** Kidney histopathology. Kidney sections were stained with PAS and hematoxylin to evaluate the grade of the glomerular damage. The figure shows representative pictures of kidney section from non-diabetic (NC), diabetic (DC), and diabetic rats treated with carnosine (DC+C). In DC and DC+C a slight increase of mesangial matrix and/or hyalinosis was evident. Concomitant with an early stage of diabetic kidney damage, no further signs of glomerulosclerosis were found in DC and DC+C.



**Fig. 3.** The influence of carnosine treatment on hyperglycemia-induced glomerular apoptosis. Apoptosis was tested by TUNEL staining and by western blot analysis using kidneys of non-diabetic (NC), diabetic (DC), and diabetic rats treated with carnosine (DC+C). Panel A: Representative pictures of kidney sections stained by TUNEL. Arrows indicate cells counted as TUNEL positive. Original magnification 400x. Panel B: Quantification of TUNEL positive cells was performed in a blinded fashion on ten randomly selected glomeruli per animal (n=4, for each group) by two independent investigators. Results are expressed as mean TUNEL positive cells/glomerular area  $\pm$  SD. Note that there is no significant difference (n.s.) in the proportion of TUNEL positive cells in NC vs. DC+C, but a significant increase in DC. \*= $p < 0.05$  compared to non-diabetic controls and #= $p < 0.05$  compared to diabetics. Panel C, E: Representative immunoblots stained with antibodies directed against bax and cytochrome c, respectively. Antibodies directed against GAPDH were used to control for equal loading. Panel D, F: Quantification of bax and cytochrome c protein expression by densitometry measurement of immunoreactive bands. A total of 5-6 animals per group were evaluated. Ratios of bax/GAPDH or cytochrome c/GAPDH were calculated to avoid loading dissimilarity errors. Results are expressed as mean ratio  $\pm$  SD relative to NC. \*= $p < 0.05$  compared to non-diabetic controls and #= $p < 0.05$  compared to diabetics.




glomerular area and diabetic with carnosine:  $0.0017 \pm 0.00022$  WT-1+ cells/glomerular area,  $p < 0.05$  and -4% compared to non-diabetics,  $p$  not significant, Fig. 4A, B).

To examine the influence of carnosine on the biochemical abnormalities induced by diabetes, the activity

of three cells damaging mechanisms investigated by western blotting. To this end, antibodies directed against nitrosylated (NT, Fig. 5A) and carboxymethyl-lysine (CML, Fig. 5C)-modified proteins as markers of oxidative stress were used. Moreover, immunoblots were incubated



**Fig. 4.** The influence of carnosine treatment on diabetic podocyte loss. Podocytes were stained with antibodies directed against wt-1 in kidney sections of non-diabetic (NC), diabetic (DC), and carnosine treated diabetic (DC+C) rats. Panel A: Representative pictures of kidney sections stained for wt-1. Arrows indicate wt-1 positive cells. Original magnification 400x. Panel B: Quantification of wt-1 positive cells was performed in a blinded fashion on ten randomly selected glomeruli per animal (n=4, for each group) by two independent investigators. Results are expressed as mean podocyte numbers relative to the corresponding glomerular area  $\pm$  SD. No significant difference (n.s.) in podocyte numbers were found between NC and DC+C, whereas podocyte numbers were significantly reduced in DC. \* $p < 0.05$  compared to non-diabetic controls and # $p < 0.05$  compared to diabetics.



with antibodies directed against methylglyoxal- (MG, Fig. 5E) and GlcNAc-modified proteins (Fig. 5G) in order to assess AGE-production and the activity of the hexosamine pathway. In diabetic kidney cortex, the levels of NT- (Fig. 5B) and of CML- (Fig. 5D) modified proteins were significantly increased (+ 167% and +88%, respectively,  $p < 0.05$  for both compared to non-diabetics). Likewise, the levels of MG- and GlcNAc-modified proteins were increased in diabetic kidney lysates (+250% and +326%, respectively compared to non-diabetics,  $p < 0.05$ , Fig. 5F and H). Carnosine treatment of diabetic rats had no effect on hyperglycemia-induced increase in NT-, CML-, MG- and N-Acetylglucosamine-protein levels (diabetic with carnosine vs. non-diabetics: +204% for NT, +122% for CML, +333% for MG and +230%, all  $p < 0.05$  compared to non-diabetics, diabetics with carnosine vs. diabetics not significant).


## Discussion

Experimental evidence suggests that the carnosine-carnosinase system might play an important role in diabetes associated complications, in particular in DN [17, 34]. Diabetic patients that are homozygous for the Mannheim allele (CTG)<sub>5</sub> are less affected by DN. This genotype is associated with a low serum CN-1 activity, most likely because the (CTG)<sub>5</sub> repeat in the signal pep-

tide of CN-1 influences CN-1 secretion [18]. Inasmuch as individuals homozygous for the Mannheim allele develop less frequently DN, it is conceivable that the protective effect of the Mannheim allele is directly related to the amount of CN-1 found in serum.

A number of studies conducted in recent years have suggested that carnosine, the substrate of CN-1, might be beneficial in relation to diabetic complications diabetes [17, 24, 34, 38]. Hence, a low carnosine turnover in (CTG)<sub>5</sub> homozygous patients could be a plausible explanation why these patients develop less frequently DN. Yet, definitive proof for the salutary effect of carnosine in terms of preventing hyperglycaemia mediated damage in renal tissue is still lacking. In the present study, we therefore investigated whether oral carnosine treatment can ameliorate early changes in kidneys of streptozotocin-induced diabetic rats. The main findings of this study are the following. Carnosine treatment prevents the up-regulation of pro-apoptotic molecules in the kidneys of diabetic rats. It also prevented podocyte loss in these rats. This is independent of major biochemical abnormalities that occur as a consequence of diabetes, since carnosine did not influence NT, CML, methylglyoxal or GlcNAc expression in kidneys of diabetic rats.

Microvascular complications in diabetic patients are for a great deal causally related to an increased production of ROS, AGEs and GlcNAc-modified proteins, evoked by chronic hyperglycemia. Based on the intrinsic



**Fig. 5.** The effect of carnosine treatment on oxidative stress, AGE formation and activity of the hexosamine pathway in diabetic kidney cortex. In order to assess the effect of carnosine treatment on hyperglycemia-induced biochemical changes, kidney cortex lysates from non-diabetic (NC), diabetic (DC), and diabetic rats treated with carnosine (DC+C) were probed with antibodies against nitrotyrosine- (NT, Fig. 4A, B) and carboxymethyl-lysine- (CML, Fig. 4C, D) modified proteins as markers of oxidative stress, methylglyoxal- (MG, Fig. 4E, F) modified proteins as a marker for AGE-production and N-acetyl-D-glucosamine- (GlcNAc, Fig. 4G, H) modified proteins as a marker for hexosamine pathway activation. Representative immunoblots (Fig. 4A, C, E, G) and corresponding densitometrical quantifications (Fig. 4B, D, F, H) show a significant increase of all the markers in diabetic kidneys, irrespective of carnosine treatment. Ratios between the different biochemical markers and GAPDH were assessed to avoid loading dissimilarity errors. A total of 3 animals per group were evaluated for each marker. Results are expressed as mean ratio  $\pm$  SD. \* $p$ <0.05 compared to non-diabetic.

biochemical properties of carnosine, i.e. antioxidant effects and inhibition of AGE formation [22, 24, 39-42], we expected that carnosine feeding would counteract these factors in kidneys of diabetic rats. Yet surprisingly, our results clearly show that carnosine feeding of diabetic rats is neither capable of preventing oxidative stress and AGE formation, nor could carnosine prevent the activation of the hexosamine pathway in our experimental setting, despite of carnosine feeding significantly increased renal carnosine concentrations. However, it is wise to take some caution in stating that carnosine has antioxidant activity, as most of the data that support this assumption are derived from *in vitro* cell culture studies [43, 44]. Similar to our findings, Aruoma et al [43] have questioned the anti-oxidative property of carnosine *in vivo* and they concluded from their study that it is possible that carnosine could act as physiological antioxidant by scavenging hydroxyl radicals, but it does not have a broad spectrum of antioxidant ac-

tivity, and its ability to inhibit lipid peroxidation is not well established.

Similarly, the ability of carnosine to inhibit AGE formation was mostly demonstrated in *in vitro* experiments. Nonetheless, it has been repeatedly shown that carnosine is protective in models of ischemia reperfusion [29-33]. In terms of oxidative challenge, these models clearly differ from the diabetic model where sustained severe hyperglycemia over a period of 3 months may yield a higher oxidative burden compared to a relative short period of ischemia. It might well be that the protective biochemical characteristics of carnosine to counteract oxidative stress and hyperglycemia-induced protein modification in the diabetic kidney are exhausted by severity and duration of experimental diabetes. Besides, it has to be admitted that the antioxidant and AGE inhibiting capacity of carnosine can still be sufficient to protect the glomerular capillaries the surrounding parenchymal cells. Such a localized effect would be bound to go unno-



ticed in western blot analysis.

Nonetheless, this study does show that carnosine has a cell protective effect in the context of diabetes, as apoptosis of glomerular cells and podocyte loss were significantly diminished by carnosine. Since carnosine is a multifunctional dipeptide involved in numerous physiological processes, e.g. pH buffering [45, 46], enzyme regulation [47], and induction of heat shock proteins [28], these properties may equally contribute to the cytoprotective effect of carnosine.

Hyperglycaemia causes mitochondrial stress, an eligible condition for the induction of apoptosis. Apoptosis is believed to play an important role in a number of glomerular diseases including DN [48], and is most likely caused by changing the balance in the expression of the anti- and pro-apoptotic molecules Bcl-2 and Bax respectively. While Bcl-2 expression may account for maintaining glomerular hypercellularity, Bax expression might be more important in cell loss leading to glomerulosclerosis. Bax forms oligomers thereby increasing mitochondrial permeability and facilitating the release of cytochrome c from the mitochondrial intermembrane space. Once released from the mitochondria, cytochrome c further activates apoptosis. In our model both bax as well as cytochrome c expression were increased in the cortex of diabetic rats, pointing out that pro-apoptotic signalling is active in the diabetic kidneys. In line with this observation, quantification of TUNEL stained kidney sections revealed increased glomerular apoptosis in diabetic rats. This shift towards apoptosis was restrained by carnosine treatment, indicating a cytoprotective effect of carnosine on glomerular cells. Recently, Isermann et al. demonstrated that DN can be prevented by protecting glomerular endothelial cells and podocytes against apoptosis [9]. Interestingly, carnosine showed similar effects as reported for activated protein C in the study of Iserman et al., in that both molecules down-regulated bax

and cytochrome c and reduced TUNEL positive cells in diabetic animals.

The increase in glomerular apoptosis, and in parallel podocyte loss, in diabetic kidneys was significantly ameliorated by carnosine treatment. Although this study did not address the exact identity of the glomerular apoptotic cells, it is likely that part of these cells were of podocyte origin, as podocyte loss and glomerular cell apoptosis coincided. In human disease and in experimental models podocyte loss has been linked to the development of proteinuria and glomerulosclerosis [49] and is predictive for the progression of DN [14, 50-52]. In keeping with the central role of podocytes in the glomerular architecture and the beneficial effect of carnosine treatment on podocyte loss, our results may indicate that carnosine could protect from DN. Moreover, the clear pro- and anti-apoptotic effect that we have observed in western blot analysis might not represent changes limited to the glomerulus and cells situated in areas outside of the glomerulus might also be protected by carnosine. Therefore, carnosine could have a broader therapeutic spectrum that goes beyond the salutary effect demonstrated in this study.

## Acknowledgements

This study was supported by Flamma S.p.a. (Chignolo d'Isola, Italy) and by grants from the Deutsche Forschungsgemeinschaft (DFG Graduiertenkolleg GRK880 for Eva Riedl and Frederick Pfister).

We thank Marika Rasche from the Institute of Clinical Chemistry, University Medicine Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany, for her excellent technical assistance for the measurement of tissue carnosine concentrations.

## References

- 1 Forbes JM, Cooper ME, Oldfield MD, Thomas MC: Role of advanced glycation end products in diabetic nephropathy. *J Am Soc Nephrol* 2003;14:S254-258.
- 2 Lee HB, Yu MR, Yang Y, Jiang Z, Ha H: Reactive oxygen species-regulated signaling pathways in diabetic nephropathy. *J Am Soc Nephrol* 2003;14:S241-245.
- 3 Schleicher ED, Weigert C: Role of the hexosamine biosynthetic pathway in diabetic nephropathy. *Kidney Int Suppl* 2000;77:S13-18.
- 4 Kang BP, Frencher S, Reddy V, Kessler A, Malhotra A, Meggs LG: High glucose promotes mesangial cell apoptosis by oxidant-dependent mechanism. *Am J Physiol Renal Physiol* 2003;284:F455-466.
- 5 Susztak K, Raff AC, Schiffer M, Bottinger EP: Glucose-induced reactive oxygen species cause apoptosis of podocytes and podocyte depletion at the onset of diabetic nephropathy. *Diabetes* 2006;55:225-233.

- 6 Yamagishi S, Inagaki Y, Okamoto T, Amano S, Koga K, Takeuchi M, Makita Z: Advanced glycation end product-induced apoptosis and overexpression of vascular endothelial growth factor and monocyte chemoattractant protein-1 in human-cultured mesangial cells. *J Biol Chem* 2002;277:20309-20315.
- 7 Baba K, Minatoguchi S, Sano H, Kagawa T, Murata I, Takemura G, Hirano T, Ohashi H, Takemura M, Fujiwara T, Fujiwara H: Involvement of apoptosis in patients with diabetic nephropathy: A study on plasma soluble fas levels and pathological findings. *Nephrology (Carlton)* 2004;9:94-99.
- 8 Kumar D, Robertson S, Burns KD: Evidence of apoptosis in human diabetic kidney. *Mol Cell Biochem* 2004;259:67-70.
- 9 Isermann B, Vinnikov IA, Madhusudhan T, Herzog S, Kashif M, Blautzik J, Corat MA, Zeier M, Blessing E, Oh J, Gerlitz B, Berg DT, Grinnell BW, Chavakis T, Esmon CT, Weiler H, Bierhaus A, Nawroth PP: Activated protein c protects against diabetic nephropathy by inhibiting endothelial and podocyte apoptosis. *Nat Med* 2007;13:1349-1358.
- 10 Jefferson JA, Shankland SJ, Pichler RH: Proteinuria in diabetic kidney disease: A mechanistic viewpoint. *Kidney Int* 2008;74:22-36.
- 11 Pagtalunan ME, Miller PL, Jumping-Eagle S, Nelson RG, Myers BD, Rennke HG, Coplon NS, Sun L, Meyer TW: Podocyte loss and progressive glomerular injury in type ii diabetes. *J Clin Invest* 1997;99:342-348.
- 12 Reddy GR, Kotlyarevska K, Ransom RF, Menon RK: The podocyte and diabetes mellitus: Is the podocyte the key to the origins of diabetic nephropathy? *Curr Opin Nephrol Hypertens* 2008;17:32-36.
- 13 Wolf G, Chen S, Ziyadeh FN: From the periphery of the glomerular capillary wall toward the center of disease: Podocyte injury comes of age in diabetic nephropathy. *Diabetes* 2005;54:1626-1634.
- 14 Meyer TW, Bennett PH, Nelson RG: Podocyte number predicts long-term urinary albumin excretion in pima indians with type ii diabetes and microalbuminuria. *Diabetologia* 1999;42:1341-1344.
- 15 Freedman BI, Bowden DW, Sale MM, Langefeld CD, Rich SS: Genetic susceptibility contributes to renal and cardiovascular complications of type 2 diabetes mellitus. *Hypertension* 2006;48:8-13.
- 16 Seaquist ER, Goetz FC, Rich S, Barbosa J: Familial clustering of diabetic kidney disease. Evidence for genetic susceptibility to diabetic nephropathy. *N Engl J Med* 1989;320:1161-1165.
- 17 Janssen B, Hohenadel D, Brinkkoetter P, Peters V, Rind N, Fischer C, Rychlik I, Cerna M, Romzova M, de Heer E, Baelde H, Bakker SJ, Zirie M, Rondeau E, Mathieson P, Saleem MA, Meyer J, Koppel H, Sauerhoefer S, Bartram CR, Nawroth P, Hammes HP, Yard BA, Zschocke J, van der Woude FJ: Carnosine as a protective factor in diabetic nephropathy: Association with a leucine repeat of the carnosinase gene cndp1. *Diabetes* 2005;54:2320-2327.
- 18 Riedl E, Koeppl H, Brinkkoetter P, Sternik P, Steinbeisser H, Sauerhoefer S, Janssen B, van der Woude FJ, Yard BA: A ctg polymorphism in the cndp1 gene determines the secretion of serum carnosinase in cos-7 transfected cells. *Diabetes* 2007;56:2410-2413.
- 19 Mooyaart AL, van Valkengoed IG, Shaw PK, Peters V, Baelde HJ, Rabelink TJ, Bruijn JA, Stronks K, de Heer E: Lower frequency of the 5/5 homozygous cndp1 genotype in south asian surinamese. *Diabetes Res Clin Pract* 2009;85:272-278.
- 20 Brownson C, Hipkiss AR: Carnosine reacts with a glycosylated protein. *Free Radic Biol Med* 2000;28:1564-1570.
- 21 Hipkiss AR, Chana H: Carnosine protects proteins against methylglyoxal-mediated modifications. *Biochem Biophys Res Commun* 1998;248:28-32.
- 22 Hipkiss AR, Michaelis J, Syrris P: Non-enzymatic glycosylation of the dipeptide l-carnosine, a potential anti-protein-cross-linking agent. *FEBS Lett* 1995;371:81-85.
- 23 Hipkiss AR, Preston JE, Himsworth DT, Worthington VC, Keown M, Michaelis J, Lawrence J, Mateen A, Allende L, Eagles PA, Abbott NJ: Pluripotent protective effects of carnosine, a naturally occurring dipeptide. *Ann N Y Acad Sci* 1998;854:37-53.
- 24 Lee YT, Hsu CC, Lin MH, Liu KS, Yin MC: Histidine and carnosine delay diabetic deterioration in mice and protect human low density lipoprotein against oxidation and glycation. *Eur J Pharmacol* 2005;513:145-150.
- 25 Fuji Y, Matura T, Kai M, Kawasaki H, Yamada K: Protection by polaprezinc, an anti-ulcer drug, against indomethacin-induced apoptosis in rat gastric mucosal cells. *Jpn J Pharmacol* 2000;84:63-70.
- 26 Matsuo-Matsuyama M, Shichijo K, Okaichi K, Nakayama T, Nakashima M, Uemura T, Niino D, Sekine I: Protection by polaprezinc against radiation-induced apoptosis in rat jejunal crypt cells. *J Radiat Res (Tokyo)* 2008;49:341-347.
- 27 Omatsu T, Naito Y, Handa O, Mizushima K, Hayashi N, Qin Y, Harusato A, Hirata I, Kishimoto E, Okada H, Uchiyama K, Ishikawa T, Takagi T, Yagi N, Kokura S, Ichikawa H, Yoshikawa T: Reactive oxygen species-quenching and anti-apoptotic effect of polaprezinc on indomethacin-induced small intestinal epithelial cell injury. *J Gastroenterol* 2010;45:692-702.
- 28 Odashima M, Otaka M, Jin M, Konishi N, Sato T, Kato S, Matsushashi T, Nakamura C, Watanabe S: Induction of a 72-kda heat-shock protein in cultured rat gastric mucosal cells and rat gastric mucosa by zinc l-carnosine. *Dig Dis Sci* 2002;47:2799-2804.
- 29 Baykara B, Tekmen I, Pekcetin C, Ulukus C, Tuncel P, Sagol O, Ormen M, Ozogul C: The protective effects of carnosine and melatonin in ischemia-reperfusion injury in the rat liver. *Acta Histochem* 2009;111:42-51.
- 30 Fouad AA, El-Rehany MA, Maghraby HK: The hepatoprotective effect of carnosine against ischemia/reperfusion liver injury in rats. *Eur J Pharmacol* 2007;572:61-68.
- 31 Fujii T, Takaoka M, Muraoka T, Kurata H, Tsuruoka N, Ono H, Kiso Y, Tanaka T, Matsumura Y: Preventive effect of l-carnosine on ischemia/reperfusion-induced acute renal failure in rats. *Eur J Pharmacol* 2003;474:261-267.
- 32 Fujii T, Takaoka M, Tsuruoka N, Kiso Y, Tanaka T, Matsumura Y: Dietary supplementation of l-carnosine prevents ischemia/reperfusion-induced renal injury in rats. *Biol Pharm Bull* 2005;28:361-363.
- 33 Kurata H, Fujii T, Tsutsui H, Katayama T, Ohkita M, Takaoka M, Tsuruoka N, Kiso Y, Ohno Y, Fujisawa Y, Shokoji T, Nishiyama A, Abe Y, Matsumura Y: Renoprotective effects of l-carnosine on ischemia/reperfusion-induced renal injury in rats. *J Pharmacol Exp Ther* 2006;319:640-647.
- 34 Sauerhoefer S, Yuan G, Braun GS, Deinzer M, Neumaier M, Gretz N, Floege J, Kriz W, van der Woude F, Moeller MJ: L-carnosine, a substrate of carnosinase-1, influences glucose metabolism. *Diabetes* 2007;56:2425-2432.
- 35 Schonherr J: Analysis of products of animal origin in feeds by determination of carnosine and related dipeptides by high-performance liquid chromatography. *J Agric Food Chem* 2002;50:1945-1950.
- 36 Hammes HP, Alt A, Niwa T, Clausen JT, Bretzel RG, Brownlee M, Schleicher ED: Differential accumulation of advanced glycation end products in the course of diabetic retinopathy. *Diabetologia* 1999;42:728-736.

- 37 Shinohara M, Thornalley PJ, Giardino I, Beisswenger P, Thorpe SR, Onorato J, Brownlee M: Overexpression of glyoxalase-I in bovine endothelial cells inhibits intracellular advanced glycation endproduct formation and prevents hyperglycemia-induced increases in macromolecular endocytosis. *J Clin Invest* 1998;101:1142-1147.
- 38 Rashid I, van Reyk DM, Davies MJ: Carnosine and its constituents inhibit glycation of low-density lipoproteins that promotes foam cell formation in vitro. *FEBS Lett* 2007;581:1067-1070.
- 39 Calabrese V, Colombrina C, Guagliano E, Sapienza M, Ravagna A, Cardile V, Scapagnini G, Santoro AM, Mangiameli A, Butterfield DA, Giuffrida Stella AM, Rizzarelli E: Protective effect of carnosine during nitrosative stress in astroglial cell cultures. *Neurochem Res* 2005;30:797-807.
- 40 Kohen R, Yamamoto Y, Cundy KC, Ames BN: Antioxidant activity of carnosine, homocarnosine, and anserine present in muscle and brain. *Proc Natl Acad Sci U S A* 1988;85:3175-3179.
- 41 Seidler NW: Carnosine prevents the glycation-induced changes in electrophoretic mobility of aspartate aminotransferase. *J Biochem Mol Toxicol* 2000;14:215-220.
- 42 Yan H, Harding JJ: Carnosine protects against the inactivation of esterase induced by glycation and a steroid. *Biochim Biophys Acta* 2005;1741:120-126.
- 43 Aruoma OI, Loughton MJ, Halliwell B: Carnosine, homocarnosine and anserine: Could they act as antioxidants in vivo? *Biochem J* 1989;264:863-869.
- 44 Decker EA, Livisay SA, Zhou S: A re-evaluation of the antioxidant activity of purified carnosine. *Biochemistry (Mosc)* 2000;65:766-770.
- 45 Davey CL: The significance of carnosine and anserine in striated skeletal muscle. *Arch Biochem Biophys* 1960;89:303-308.
- 46 Dunnett M, Harris RC: Influence of oral beta-alanine and L-histidine supplementation on the carnosine content of the gluteus medius. *Equine Vet J Suppl* 1999;30:499-504.
- 47 Johnson P, Aldstadt J: Effects of carnosine and anserine on muscle and non-muscle phosphorylases. *Comp Biochem Physiol B* 1984;78:331-333.
- 48 Yoshimura A, Uda S, Inui K, Nemoto T, Sugeno Y, Sharif S, Yokota N, Watanabe S, Ideura T: Expression of bcl-2 and bax in glomerular disease. *Nephrol Dial Transplant* 1999;14 Suppl 1:55-57.
- 49 Kriz W, Gretz N, Lemley KV: Progression of glomerular diseases: Is the podocyte the culprit? *Kidney Int* 1998;54:687-697.
- 50 Mundel P, Shankland SJ: Podocyte biology and response to injury. *J Am Soc Nephrol* 2002;13:3005-3015.
- 51 Nakamura T, Ushiyama C, Suzuki S, Hara M, Shimada N, Ebihara I, Koide H: The urinary podocyte as a marker for the differential diagnosis of idiopathic focal glomerulosclerosis and minimal-change nephrotic syndrome. *Am J Nephrol* 2000;20:175-179.
- 52 Steffes MW, Schmidt D, McCrery R, Basgen JM: Glomerular cell number in normal subjects and in type 1 diabetic patients. *Kidney Int* 2001;59:2104-2113.